Side effects
If you experience any strange side effects while taking this medication, contact your doctor right away. The Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program is available online at http://www.fda.gov/Safety/MedWatch or by phone at 1-800-332-1088 if you or your doctor notice a serious side effect. Call your doctor right away if you experience any of the following symptoms or any of those mentioned in the SPECIAL PRECAUTIONS section: back pain sinus pain and congestion diarrhea swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs hoarseness difficulty breathing or swallowing pain and cramping in the lower leg that comes and goes during walking or exercise blistering of the skin or rash Telmisartan may also cause other side effects. Tell your doctor if any of these symptoms are severe or persistent, including back pain, sinus pain, diarrhea, swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs, hoarseness, difficulty breathing, or a rash or blisters on the skin. Some side effects can be very serious. Aside effects from telmisartan are possible.
Interactions
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.
Contraindications
Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker. Don't expose fetuses or newborns. Hypotension. Patients with impaired renal or hepatic function should be closely monitored.
Telmisartan/amlodipine, sold under the brand name Twynsta among others, is a medication used to treat high blood pressure. The combination is on the World Health Organization's List of Essential Medicines. It is a combination of telmisartan an angiotensin II receptor antagonist with amlodipine a calcium channel blocker. Severe side effects may include low blood pressure, kidney problems, electrolyte problems, and a heart attack.
• Telmisartan/Hydrochlorothiazide 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Telmisartan/Hydrochlorothiazide 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. In patients with mild to moderate hepatic impairment the posology should not exceed Telmisartan/Hydrochlorothiazide 40 mg/12.5 mg once daily. The safety and efficacy of Telmisartan/Hydrochlorothiazide in children and adolescents aged below 18 have not been established.
This medication is tolerated well by most patients and has few facet effects. Before taking this medication, let your doctor know if you have got any urinary organ or liver issues. It may be taken with or without food during the day or at night.
It is not known whether doses lower than 80 mg of telmisartan are effective in reducing cardiovascular morbidity. No posology adjustment is required for patients with mild to moderate renal impairment. Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
We have all India marketing network to serve pharma industry in the best way by providing the latest and sophisticated molecules with quality and batch to batch consistency. Biomax Biotechnics Private Limited is one of the leading Pharma Companies in India with Corporate office based at Chandigarh.